Browsing by Author "Devillier P."

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    ItemMetadata only
    Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments
    (2026-04-01) Sousa-Pinto B.; Bousquet J.; Vieira R.J.; Schünemann H.J.; Zuberbier T.; Bognanni A.; Togias A.; Samolinski B.; Valiulis A.; Williams S.; Bedbrook A.; Czarlewski W.; Torres M.J.; Shamji M.H.; Morais-Almeida M.; Canonica G.W.; Vecillas L.d.l.; Dykewicz M.S.; Jacomelli C.; Klimek L.; Leemann L.; Lourenço O.; Palamarchuk Y.; Papadopoulos N.G.; Pereira A.M.; Savouré M.; Toppila-Salmi S.K.; Ventura M.T.; Yepes-Nuñez J.J.; Cruz A.A.; Ciprandi G.; Gemicioglu B.; Giovannini M.; Gradauskiene B.; Jartti T.; Jeseňák M.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.E.; Latiff A.H.A.; Mohammad Y.; Ohta K.; Mahesh P.A.; Pali-Schöll I.; Pfaar O.; Regateiro F.S.; Roche N.; Taborda-Barata L.; Ulrik C.S.; Rostan M.V.; Viegi G.; Zhang L.; Haahtela T.; Cherrez-Ojeda I.; Carlos Ivancevich J.; Khaltaev N.; Yorgancioglu A.; Abdullah B.; Al-Ahmad M.; Al-Nesf M.A.; Amaral R.; Asllani J.; Bergmann K.C.; Bernstein J.A.; Blaiss M.S.; Braido F.; Camargos P.; Carreiro-Martins P.; Casale T.; Cecchi L.; Fiocchi A.; Giuliano A.F.M.; Christoff G.; Cirule I.; de Sousa J.C.; Costa E.M.; Del Giacco S.; Devillier P.; Dokic D.; Hossny E.; Iinuma T.; Irani C.; Ispayeva Z.; Julge K.; Kaidashev I.; Bennoor K.S.; Kraxner H.; Kull I.; Kulus M.; Kupczyk M.; Kurchenko A.; La Grutta S.; Miculinic N.; Tuyet L.L.T.; Makris M.; Milenkovic B.; Lee S.M.; Montefort S.; Moreira A.; Mullol J.; Sousa-Pinto B.; Mahidol University
    Background: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management. Methods: The ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs. Results: Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH. Conclusion: This ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.
  • No Thumbnail Available
    ItemMetadata only
    Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments
    (2026-01-01) Vieira R.J.; Sousa-Pinto B.; Bousquet J.; Schünemann H.J.; Zuberbier T.; Bognanni A.; Togias A.; Samolinski B.; Valiulis A.; Williams S.; Bedbrook A.; Czarlewski W.; Torres M.J.; Shamji M.H.; Morais-Almeida M.; Canonica G.W.; Vecillas L.d.l.; Dykewicz M.S.; Jacomelli C.; Klimek L.; Leemann L.; Lourenço O.; Papadopoulos N.G.; Pereira A.M.; Savouré M.; Toppila-Salmi S.K.; Ventura M.T.; Yepes-Nuñez J.J.; Cruz A.A.; Ciprandi G.; Gemicioglu B.; Giovannini M.; Gradauskiene B.; Jartti T.; Jeseňák M.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.E.; Latiff A.H.A.; Mohammad Y.; Ohta K.; Mahesh P.A.; Pali-Schöll I.; Pfaar O.; Regateiro F.S.; Roche N.; Taborda-Barata L.; Ulrik C.S.; Viegi G.; Zhang L.; Haahtela T.; Cherrez-Ojeda I.; Ivancevich J.C.; Khaltaev N.; Yorgancioglu A.; Abdullah B.; Al-Ahmad M.; Al-Nesf M.A.; Amaral R.; Asllani J.; Bergmann K.C.; Bernstein J.A.; Blaiss M.S.; Toskala E.; Carreiro-Martins P.; Casale T.; Cecchi L.; Fiocchi A.; Giuliano A.F.M.; Christoff G.; Cirule I.; de Sousa J.C.; Costa E.M.; Devillier P.; Hossny E.; Iinuma T.; Ispayeva Z.; Julge K.; Kaidashev I.; Bennoor K.S.; Kraxner H.; Kull I.; Kulus M.; Kupczyk M.; Kurchenko A.; La Grutta S.; Miculinic N.; Tuyet L.L.T.; Lee S.M.; Montefort S.; Moreira A.; Mullol J.; Nadif R.; Nakonechna A.; Neffen H.E.; Niedoszytko M.; O'Hehir R.E.; Ogulur I.; Okamoto Y.; Olze H.; Vieira R.J.; Mahidol University
    Background: Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines, this manuscript presents the ARIA-EAACI 2024–2025 recommendations for oral and ocular treatments. Methods: The ARIA-EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results: Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion: This ARIA-EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.
  • No Thumbnail Available
    ItemMetadata only
    Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
    (2024-01-01) Bousquet J.; Schünemann H.J.; Sousa-Pinto B.; Zuberbier T.; Togias A.; Samolinski B.; Bedbrook A.; Czarlewski W.; Hofmann-Apitius M.; Litynska J.; Vieira R.J.; Anto J.M.; Fonseca J.A.; Brozek J.; Bognanni A.; Brussino L.; Canonica G.W.; Cherrez-Ojeda I.; Cruz A.A.; Vecillas L.d.l.; Dykewicz M.; Gemicioglu B.; Giovannini M.; Haahtela T.; Jacobs M.; Jacomelli C.; Klimek L.; Kvedariene V.; Larenas-Linnemann D.E.; Louis G.; Lourenço O.; Leemann L.; Morais-Almeida M.; Neves A.L.; Nadeau K.C.; Nowak A.; Palamarchuk Y.; Palkonen S.; Papadopoulos N.G.; Parmelli E.; Pereira A.M.; Pfaar O.; Regateiro F.S.; Savouré M.; Taborda-Barata L.; Toppila-Salmi S.K.; Torres M.J.; Valiulis A.; Ventura M.T.; Williams S.; Yepes-Nuñez J.J.; Yorgancioglu A.; Zhang L.; Zuberbier J.; Abdul Latiff A.H.; Abdullah B.; Agache I.; Al-Ahmad M.; Al-Nesf M.A.; Al Shaikh N.A.; Amaral R.; Ansotegui I.J.; Asllani J.; Balotro-Torres M.C.; Bergmann K.C.; Bernstein J.A.; Bindslev-Jensen C.; Blaiss M.S.; Bonaglia C.; Bonini M.; Bossé I.; Braido F.; Caballero-Fonseca F.; Camargos P.; Carreiro-Martins P.; Casale T.; Castillo-Vizuete J.A.; Cecchi L.; Teixeira M.d.C.; Chang Y.S.; Loureiro C.C.; Christoff G.; Ciprandi G.; Cirule I.; Correia-de-Sousa J.; Costa E.M.; Cvetkovski B.; de Vries G.; Del Giacco S.; Devillier P.; Dokic D.; Douagui H.; Durham S.R.; Enecilla M.L.; Fiocchi A.; Fokkens W.J.; Fontaine J.F.; Gawlik R.; Gereda J.E.; Gil-Mata S.; Bousquet J.; Mahidol University
    The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients’ resources and abilities to be experts in their own lives based on their lived experiences. Improving healthcare safety, quality, and coordination, as well as quality of life, is an important aim in the care of patients with chronic conditions. Person-centered care needs to ensure that people's values and preferences guide clinical decisions. This paper reviews current knowledge to develop (1) digital care pathways for rhinitis and asthma multimorbidity and (2) digitally enabled, person-centered care.1 It combines all relevant research evidence, including the so-called real-world evidence, with the ultimate goal to develop digitally enabled, patient-centered care. The paper includes (1) Allergic Rhinitis and its Impact on Asthma (ARIA), a 2-decade journey, (2) Grading of Recommendations, Assessment, Development and Evaluation (GRADE), the evidence-based model of guidelines in airway diseases, (3) mHealth impact on airway diseases, (4) From guidelines to digital care pathways, (5) Embedding Planetary Health, (6) Novel classification of rhinitis and asthma, (7) Embedding real-life data with population-based studies, (8) The ARIA-EAACI (European Academy of Allergy and Clinical Immunology) strategy for the management of airway diseases using digital biomarkers, (9) Artificial intelligence, (10) The development of digitally enabled, ARIA person-centered care, and (11) The political agenda. The ultimate goal is to propose ARIA 2024 guidelines centered around the patient to make them more applicable and sustainable.
  • No Thumbnail Available
    ItemMetadata only
    Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
    (2026-02-01) Bousquet J.; Sousa-Pinto B.; Vieira R.J.; Schünemann H.J.; Zuberbier T.; Bognanni A.; Togias A.; Samolinski B.; Valiulis A.; Williams S.; Bedbrook A.; Czarlewski W.; Torres M.J.; Shamji M.H.; Morais-Almeida M.; Canonica G.W.; Vecillas L.d.l.; Dykewicz M.S.; Jacomelli C.; Klimek L.; Leemann L.; Lourenço O.; Palamarchuk Y.; Papadopoulos N.G.; Pereira A.M.; Savouré M.; Toppila-Salmi S.K.; Ventura M.T.; Yepes-Nuñez J.J.; Cruz A.A.; Ciprandi G.; Gemicioglu B.; Giovannini M.; Gradauskiene B.; Jartti T.; Jeseňák M.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.E.; Latiff A.H.A.; Mohammad Y.; Ohta K.; Mahesh P.A.; Pali-Schöll I.; Pfaar O.; Regateiro F.S.; Roche N.; Sofiev M.; Taborda-Barata L.; Ulrik C.S.; Rostan M.V.; Viegi G.; Zhang L.; Antó J.M.; Haahtela T.; Cherrez-Ojeda I.; Ivancevich J.C.; Khaltaev N.; Yorgancioglu A.; Abdullah B.; Al-Ahmad M.; Al-Nesf M.A.; Amaral R.; Asllani J.; Bergmann K.C.; Bernstein J.A.; Blaiss M.S.; Braido F.; Camargos P.; Carreiro-Martins P.; Casale T.; Cecchi L.; Fiocchi A.G.; Giuliano A.F.M.; Christoff G.; Cirule I.; Correia-de-Sousa J.; Costa E.M.; Del Giacco S.; Devillier P.; Dokic D.; Hossny E.; Iinuma T.; Irani C.; Ispayeva Z.; Julge K.; Kaidashev I.; Bennoor K.S.; Kraxner H.; Kull I.; Kulus M.; Kupczyk M.; Kurchenko A.; La Grutta S.; Miculinic N.; Tuyet L.L.T.; Makris M.; Milenkovic B.; Lee S.M.; Montefort S.; Bousquet J.; Mahidol University
    The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines produced their first edition in 1999, with subsequent revisions in 2008, 2010, 2016 and 2019. A new iteration of ARIA—ARIA 2024–2025—in collaboration with EAACI is currently being developed, focusing on the management of allergic rhinitis. ARIA 2024–2025 follows the GRADE framework and is endorsed by the European Academy of Allergy and Clinical Immunology (EAACI). A set of approaches has been used to develop guideline questions, including surveying key opinion leaders and using artificial intelligence (AI)-based tools to analyse web searches on allergic rhinitis and to generate questions. Each prioritised guideline question is assessed through an Evidence-to-Decision (EtD) framework. EtDs support the systematic and transparent formulation of recommendations, comprising 12 criteria for which the best available evidence should be sought. In the context of ARIA-EAACI 2024–2025, such evidence is derived not only from randomised controlled trials but also—among others—from patient-generated data sources that better reflect the affected individuals' perspectives. Moreover, ARIA-EAACI 2024–2025 incorporates evidence on planetary health. Developed guideline recommendations will support the creation of digitalised decision algorithms and care pathways. This paper describes the methodology used to develop the person-centred, digitally enabled and AI-assisted ARIA-EAACI 2024–2025. Among others, it describes (i) the development and prioritisation of guideline questions, (ii) sources of evidence for EtDs and (iii) the development of digitalised decision algorithms and care pathways.